In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Neuroprotective Agents (3)

Edited by Edited by William Slikker, Jr. (National Center for Toxicological Research, FDA, Jefferson, Arkansas), Russell J. Andrews (NASA Ames Research Center, Moffet Field, California), and Bruce Trembly (Veterans Affairs Medical Center, Togus, Maine)
Neuroprotective Agents (3)

Published: September 2005

Volume 1053

Learn More

As life expectancy has increased, so has the incidence of neurodegenerative diseases, particularly those associated with aging. Contributing to increased life expectancy is increased survival following brain injury, stroke, and procedures such as heart surgery, but these events can impair neurological function. The wide range of contributions to this volume, from a detailed paper on the use of gene therapy in combination with hypothermia for the treatment of cerebral ischemia to a comprehensive poster describing the role of anesthetic agents in neurotoxicity during development and senescence, illustrate the scientific scope presented. Contributions from clinical and basic science researchers from many disciplines address various approaches to providing neuroprotection. The clinical focus is on the complexity of neuroprotection, the need for understanding the time-course effects of hypoxia/ischemia, and the need for combinational and time-course applications of multiple therapies. New technologies are introduced for describing both the insult and the treatment necessary for neuroprotection, including gene expression assays (genomics) and gene therapy.